Second-generation inhibitors (e.g., panobinostat, romidepsin) further exhibit blood–brain barrier penetration efficacy and display promise in central nervous system-metastasized NB subtypes (25), with six active HDAC-targeted clinical trials currently recruiting pediatric patients with NB. Here, HDAC9 is linked to neuroblastoma.